Adaptive clinical trial designs with pre-specified rules for modifying the sample size: Understanding efficient types of adaptation

Statistics in Medicine

Volumn 32, Issue 8, 2013, Pages 1259-1275

  Levin, Gregory P ^a   Emerson, Sarah C ^b   Emerson, Scott S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Adaptive designs; Clinical trials; Efficiency; Group sequential tests; Sample size modification; Sufficiency

Indexed keywords

ADAPTIVE CLINICAL TRIAL DESIGN; ALTERNATIVE HYPOTHESIS; ARTICLE; BIVARIATE ANALYSIS; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MAXIMUM LIKELIHOOD METHOD; NULL HYPOTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SAMPLING; STATISTICAL DISTRIBUTION; STRATEGIC PLANNING; STUDY DESIGN;

DATA INTERPRETATION, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84875268645     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5662     Document Type: Article

References (37)

1. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50(4):1029-1041.
2. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51(4):1315-1324.
3. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. International Biometric Society 2001; 57(3):886-891.
4. Fisher LD. Self-designing clinical trials. Statistics in Medicine 1998; 17:1551-1562.
5. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857.
6. Mehta C, Pocock S. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Statistics in Medicine 2011; 30(28):3267-3284.
7. Liu Q, Anderson KM. On adaptive extensions of group sequential trials for clinical investigations. Journal of the American Statistical Association 2008; 103(484):1621-1630.
8. Emerson SS, Levin GP, Emerson SC. Comments on 'adaptive increase in sample size when interim results are promising: a practical guide with examples'. Statistics in Medicine 2011; 30(28):3285-3301.
9. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90(2):367-378.
10. Jennison C, Turnbull BW. Adaptive and nonadaptive group sequential tests. Biometrika 2006; 93(1):1-21.
11. Jennison C, Turnbull BW. Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine 2003; 22:971-993.
12. Schmitz N. Optimal Sequentially Planned Decision Procedures. Springer-Verlag: New York, 1991.
13. Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics, 2010.
14. Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 2006; 25:917-932.
15. Benerjee A, Tsiatis AA. Adaptive two-stage designs in phase II clinical trials. Statistics in Medicine 2006; 25:3382-3395.
16. Lokhnygina Y, Tsiatis AA. Optimal two-stage group-sequential designs. Journal of Statistical Planning and Inference 2008; 138:489-499.
17. S+SeqTrial. Insightful corporation, 2002. Seattle, Washington.
18. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC: Boca Raton, 2000.
19. Kittelson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 1999; 55:874-882.
20. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987; 43:193-199.
21. Emerson SS, Fleming TR. Symmetric group sequential test designs. Biometrics 1989; 45(3):905-923.
22. Jennison C. Efficient group sequential tests with unpredictable group sizes. Biometrika 1987; 74:155-165.
23. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society: Series A 1969; 132:235-244.
24. Emerson SC, Rudser KD, Emerson SS. Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings. Statistics in Medicine 2011; 30(11):1199-1217.
25. Emerson SS, Fleming TR. Parameter estimation following group sequential hypothesis testing. Biometrika 1990; 77(4):875-892.
26. Chang MN, O'Brien PC. Confidence intervals following group sequential tests. Controlled Clinical Trials 1986; 7:18-26.
27. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics 1984; 40(3):797-803.
28. Rosner GL, Tsiatis AA. Exact confidence intervals following a group sequential test: a comparison of methods. Biometrika 1988; 75:723-729.
29. Chang MN. Confidence intervals for a normal mean following a group sequential test. Biometrics 1989; 45:247-254.
30. Chang MN, Gould AL, Snapinn SM. P-values for group sequential testing. Biometrika 1995; 82(3):650-654.
31. Gillen DL, Emerson SS. A note on p-values under group sequential testing and nonproportional hazards. Biometrics 2005; 61(2):546-551.
32. Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009; 65:539-546.
33. Liu Q, Proschan MA, Pledger GW. A unified theory of two-stage adaptive designs. Journal of the American Statistical Association 2002; 97(460):1034-1041.
34. Whitehead J. Overrunning and underrunning in sequential clinical trials. Controlled Clinical Trials 1992; 13:106-121.
35. Hall WJ, Liu A. Sequential tests and estimators after overrunning based on maximum-likelihood ordering. Biometrika 2002; 89(3):699-707.
36. Gao P, Ware J, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. Journal of Biopharmaceutical Statistics 2008; 18(6):1184-1196.
37. Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Statistics in Medicine 2007; 26:5047-5080.